title: Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure).
abstract: OBJECTIVE
  Excess aldosterone activity contributes to the pathogenesis and progression of heart failure (HF). Aldosterone antagonists improve clinical outcome in patients with severe HF or left ventricular (LV) dysfunction after myocardial infarction, but knowledge of their impact in mild chronic HF is sparse. AREA IN-CHF was planned to investigate the effects of canrenone on progression of LV remodelling in mild HF.
  
  
  METHODS
  AREA IN-CHF is a multicentre, randomised, double-blind, parallel group comparison of canrenone (up to 50 mg/day) versus placebo in mild stable HF. The primary endpoint is change in echocardiographic LV end-diastolic volume over 12 months. Patients had New York Heart Association class II HF, LV ejection fraction < or =45%, stable standard therapy, creatinine < or =2.5 mg/dl, potassium < or =5.0 mmol/l. Follow-up examinations were scheduled monthly for the first 3 months and every 3 months thereafter. Aldosterone was measured at baseline, brain natriuretic peptide and procollagen type III amino-terminal peptide (PIIINP) at baseline and at 6 months. Echocardiography was performed at baseline, at 6 and 12 months.
  
  
  RESULTS
  Among 467 patients, median age 64 years (interquartile range (IQR) 56-70 years), 84% were men, 52% had ischaemic HF, 96% were receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, 79% beta-blockers. Brain natriuretic peptide, aldosterone and PIIINP were 88 pg/ml (IQR 35-185 pg/ml), 118 pg/ml (IQR 75-177 pg/ml), and 5.38 microg/l (IQR 3.98-7.14 microg/l), respectively. LV end-diastolic volume was 79 ml/m (IQR 64-105 ml/m) and LV ejection fraction was 40% (IQR 33-45%).
  
  
  CONCLUSIONS
  The role of aldosterone blockade in patients with mild HF remains to be established. AREA IN-CHF is addressing this issue in a large population on optimal medical therapy.
authors: Department of Cardiology, San Giovanni Addolorata Hospital, Rome, Italy. centro_studi@anmco.it
authors: Alessandro
authors: A
authors: Boccanelli
authors: Giuseppe
authors: G
authors: Cacciatore
authors: Gian Francesco
authors: GF
authors: Mureddu
authors: Giovanni
authors: G
authors: de Simone
authors: Francesco
authors: F
authors: Clemenza
authors: Renata
authors: R
authors: De Maria
authors: Andrea
authors: A
authors: Di Lenarda
authors: Antonello
authors: A
authors: Gavazzi
authors: Roberto
authors: R
authors: Latini
authors: Serge
authors: S
authors: Masson
authors: Maurizio
authors: M
authors: Porcu
authors: Massimo
authors: M
authors: Vanasia
authors: Lucio
authors: L
authors: Gonzini
authors: Aldo Pietro
authors: AP
authors: Maggioni
mesh_terms: D000368:Aged; D000450:Aldosterone / Q000097:blood; D015415:Biomarkers / Q000097:blood; D002192:Canrenone / Q000494:pharmacology / Q000627:therapeutic use*; D018450:Disease Progression; D004311:Double-Blind Method; D004452:Echocardiography; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D018487:Ventricular Dysfunction, Left / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy; D020257:Ventricular Remodeling / Q000187:drug effects*
chemical_list: D015415:Biomarkers; D000451:Mineralocorticoid Receptor Antagonists; D000450:Aldosterone; D002192:Canrenone